These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36434677)

  • 41. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 42. Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
    Bran DM; Fuks D; Lansier A; Gallois C; Karoui M; Taieb J; Lahlou W
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101920. PubMed ID: 35390538
    [No Abstract]   [Full Text] [Related]  

  • 43. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
    Rabehi T; Quesada S
    Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
    [No Abstract]   [Full Text] [Related]  

  • 44. Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma.
    Chrystle M; Sanyo D
    BMJ Case Rep; 2023 Mar; 16(3):. PubMed ID: 36863754
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
    Neuzillet C
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):773-775. PubMed ID: 34358483
    [No Abstract]   [Full Text] [Related]  

  • 46. [Systemic treatment of liver and biliary tumors].
    Malek NP; Greten T; Kubicka S
    Internist (Berl); 2007 Jan; 48(1):46-9. PubMed ID: 17177032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
    Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer.
    De SK
    Curr Med Chem; 2024; 31(6):666-670. PubMed ID: 37062061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
    Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic Artery Infusion Pump (HAIP) Therapy Versus Chemotherapy in the First-Line Setting for Patients with Unresectable Intrahepatic Cholangiocarcinoma.
    Rossi AJ; Khan TM; Luna AJ; Cercek A; Jarnagin WR; Hernandez JM
    Ann Surg Oncol; 2022 Jan; 29(1):35-36. PubMed ID: 34117578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does aspirin use influence hepatocellular carcinoma and cholangiocarcinoma prognosis?
    Stefanini B; Tonnini M; Marseglia M; Tovoli F
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):887-889. PubMed ID: 35866267
    [No Abstract]   [Full Text] [Related]  

  • 56. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
    Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Koo SH; Ihm CH; Kwon KC; Park JW; Kim JM; Kong G
    Cancer Genet Cytogenet; 2001 Oct; 130(1):22-8. PubMed ID: 11672769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PTPN3 mutations and HBV may exert synergistic effects in the origin of the intrahepatic cholangiocarcinoma.
    Cardinale V; Alvaro D
    Gastroenterology; 2014 Sep; 147(3):719-20. PubMed ID: 25075940
    [No Abstract]   [Full Text] [Related]  

  • 60. [A Case of Long-Term Survival of a Patient with Cholangiocarcinoma and Liver Metastatic Recurrence Who Responded to Gemcitabine plus Cisplatin Therapy].
    Yachi T; Kimura N; Ishido K; Kudo D; Sakuraba S; Hakamada K
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):1991-1993. PubMed ID: 30692421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.